The Tsaritsynsky social services center is testing CellAirFusion, a device that helps improve endurance in intermittent hypoxic-hyperoxic therapy.
The device was among solutions submitted to a recent contest held under the Open Challenges program. CellAirFusion helps prevent strokes, myocardial infarction, and other cardiovascular diseases. It can also be used as part of treatment and rehabilitation programs.
The device combines the advantages of a traditional hypoxicator with those of an oxygen pressure chamber.
The international Open Challenges program is designed to identify and test innovative solutions that meet Moscow's needs across a wide range of industries.